BREAKING: FDA grants full approval of Alzheimer’s drug Leqembi, amid concerns about its safety, cost and accessibility. The move marks the first time that a drug meant to slow the progression of the disease has been granted full regulatory approval.
on Thursday fully approved the Alzheimer’s drug Leqembi, amid concerns about its safety, cost and accessibility.has been granted full regulatory approval. Other approved drugs only target its symptoms.
The treatment could"give people in the early stages of Alzheimer’s more time to maintain their independence and do the things they love," Joanne Pike, president and CEO of the Alzheimer’s Association, said in a statement.How does Leqembi help Alzheimer's patients?that focused on how well patients performed in six categories: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care.
"In real-world terms, this likely means more time for the patient to be living independently, enjoying their hobbies, their friends and having a better quality of life," Wilcock said."Time will tell how much, but the clinical trial did show significant benefit on activities of daily living measures."Others, however, were less rosy about Leqembi's benefits.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
FDA to grant full approval for Alzheimer's medication LecanemabIf the FDA grants Lecanemab full approval, medical experts say Medicaid and Medicare will likely cover it MORE ⬇️
Leer más »
FDA to decide on Alzheimer’s drug approvalFull approval would likely prompt the Centers for Medicare and Medicaid Services to change how it covers the drug, broadening access for up to about a million people with early onset Alzheimer’s.
Leer más »
FDA to decide on Alzheimer’s drug approvalFull approval would likely prompt the Centers for Medicare and Medicaid Services to change how it covers the drug, broadening access for up to about a million people with early onset Alzheimer’s.
Leer más »
FDA to make a decision on whether to approve first Alzheimer’s drugThe FDA is set to decide whether it will fully approve the first Alzheimer’s drug to show it could slow the disease’s progression in certain patients. But the decision could also have other implications, including who would get access to it.
Leer más »
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverageLeqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.
Leer más »
Fiona Phillips: How common is early Alzheimer's?We answer the questions you're asking about Alzheimer's disease, which causes dementia.
Leer más »